Neuralstem, Inc.’s Phase I stem cell ALS trial has passed muster with Emory University’s Institutional Review Board. Approved by the USFDA in September 2009, the trial will take place at the Emory ALS Center, with Dr. Jonathan Glass M.D. (Director of the Emory ALS Center) serving as site PI. Patients will be treated with spinal injections of Neuralstem’s patented human neural stem cells. This Phase I trial will include eighteen patients, and is designed to evaluate the safety of the cells and the surgery. The company raised an additional $1.5 million in private placement of stock after its partnership with Emory was signed.
Click here to read more.Share this: